

10 January 2024  
ASX Code: MXC  
LSE Code: MXC

## Notice Under Section 708A(5) of the Corporations Act 2001 (the Act)

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

This notice is given by MGC Pharmaceuticals Limited (ASX: MXC) (“**MGC Pharma**” or the “**Company**”) in relation to the issue of 7,360,000 fully paid ordinary shares (**Shares**) as detailed in the Appendix 2A’s announced today.

The Corporations Act 2001 (Cth) (Act) restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, the Shares detailed in the Appendix 2A’s announced on 10 January 2024 will fall within the exemption in section 708A(5) of the Act. Pursuant to section 708A(5)(e) of the Act, the Company gives notice that:

- a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- b) as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and sections 674 and 674A of the Act; and
- c) as at the date of this notice there is no information:
  - i. that has been excluded from a continuous disclosure notice in accordance with the Listing Rules; and
  - ii. that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of:
    - 1) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - 2) the rights and liabilities attaching to the Shares.

—Ends—

**Authorised for release by the board of directors, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@mgcpharma.co.uk](mailto:info@mgcpharma.co.uk)

**UK IR/PR Advisers**

**IFC Advisory**  
Graham Herring / Tim Metcalfe / Zach Cohen  
+44 203 934 6630  
[mgcpharma@investor-focus.co.uk](mailto:mgcpharma@investor-focus.co.uk)

**MGC Pharmaceuticals Ltd**

Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@mgcpharma.co.uk](mailto:info@mgcpharma.co.uk)

**UK Brokers**

**Oberon Capital**  
Aimee McCusker / Adam Pollock  
+44 203 179 5300  
[aimeemccusker@oberoninvestments.com](mailto:aimeemccusker@oberoninvestments.com)  
[adampollock@oberoninvestments.com](mailto:adampollock@oberoninvestments.com)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

*Follow us through our social media channels:*

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC\_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc\_pharma